Pasar al contenido principal

Conexión rápida

Attend MAGHREB PHARMA Expo 2023 to join the conversation with our team

Join us to discover revolutionary
solutions for accelerating access and
affordability for patients

Attend MAGHREB PHARMA Expo 2023
to join the conversation with our team

7 - 9 February 2023
Centre International des Conférences d'Alger - CICAlgiers - Algeria
Contact Us

Our Team at MAGHREB PHARMA Expo 2023

About MAGHREB PHARMA Expo 2023

MAGHREB PHARMA Expo 2023 is the premier African pharmaceutical industry event. For the past 9 years, the expo has established itself as the go-to platform for pharmaceutical industry professionals in the region.

Maghreb Pharma Expo

The expo brings together a diverse range of exhibitors showcasing the latest innovations in the field including pharmaceutical ingredients, cutting-edge production lines, advanced packaging solutions, state-of-the-art clean rooms, treatment systems for air, water production, sterile lines, biotech reactors, laboratory equipment, and quality control technologies.

With over 2,600 decision-makers in attendance from Algeria, Morocco, Tunisia, Mali, Mauritania, Libya, and beyond, the expo provides a unique opportunity for exhibitors to connect with key players in the industry and showcase their products and services to a highly engaged and qualified audience.

In addition to the exhibition, the expo also features a comprehensive conference program, including "learnshop" sessions where industry experts will be sharing their insights and knowledge on the latest developments in the pharmaceutical industry. These sessions are designed to provide valuable information and offer opportunities to network with other professionals in the field.

We look forward to meeting you at MAGHREB PHARMA Expo 2023, an event that is sure to inspire, inform and engage industry professionals. Come and be a part of the conversation shaping the future of the pharmaceutical industry in Africa.

About Dr.Reddy’s API Business

We specialise in manufacturing and supplying a wide range of APIs for generic formulation manufacturers in India and overseas. The company has a diversified portfolio of 150+ active pharmaceutical ingredients, which are used in major therapeutic areas such as gastrointestinal, cardiovascular, diabetology, oncology, pain management, and dermatology. Our API manufacturing facilities adhere to cGMP (ICH Q7) and are inspected on a regular basis by international regulatory bodies. We have eight commercially inspected USFDA production plants, six in India and one each in Mexico and the United Kingdom.

About Dr.Reddy’s API Business

Dr. Reddy's API business operates in a number of global markets, including the United States of America, Latin America, Europe, India, Russia, and other CIS nations.


Dr. Reddy's is among the top sustainable pharmaceutical companies globally. We are listed in the sustainability yearbook of S&P 2022 for the second year in a row and the Bloomberg Gender-Equality Index (GEI) for the fifth consecutive year. In addition, we were ranked ninth in the Dow Jones Sustainability Index (DJSI) 2021 among the most sustainable pharmaceutical companies in the world. In our sustainability journey, these accolades are humbling and demonstrate that we're on the right track. These awards recognize our consistent performance in the environment, social, and governance (ESG) framework. Sustainability and ESG are becoming increasingly important topics for all stakeholders, so we will strive to maintain visibility in these areas.


Our Achievements

Our plants

Dr. Reddy’s API  Manufacturing Locations


Ninguna información en este catálogo, incluida cualquier referencia a cualquier producto o servicio, constituye una oferta de venta, ni debe interpretarse como representación de una oferta de venta. Los productos protegidos por patentes válidas no se ofrecen ni se suministran para uso comercial. Sin embargo, las cantidades de investigación de dichos productos pueden ofrecerse con el fin de presentaciones reglamentarias, siempre que existan dichas exenciones reglamentarias. Los compradores deben realizar una evaluación independiente del escenario de la patente para sus respectivos mercados y serán responsables de todas las responsabilidades relacionadas con la patente. Los productos protegidos por patentes válidas en la India no están disponibles para uso comercial, pero estarían disponibles para los fines de la Sección 107A.